JP2019515646A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515646A5 JP2019515646A5 JP2018544554A JP2018544554A JP2019515646A5 JP 2019515646 A5 JP2019515646 A5 JP 2019515646A5 JP 2018544554 A JP2018544554 A JP 2018544554A JP 2018544554 A JP2018544554 A JP 2018544554A JP 2019515646 A5 JP2019515646 A5 JP 2019515646A5
- Authority
- JP
- Japan
- Prior art keywords
- binding member
- seq
- member according
- sequence
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020057.2 | 2016-02-25 | ||
| EP16020057 | 2016-02-25 | ||
| PCT/EP2017/054367 WO2017144681A1 (en) | 2016-02-25 | 2017-02-24 | Binding members to pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515646A JP2019515646A (ja) | 2019-06-13 |
| JP2019515646A5 true JP2019515646A5 (https=) | 2020-04-09 |
| JP7080819B2 JP7080819B2 (ja) | 2022-06-06 |
Family
ID=55446573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545230A Expired - Fee Related JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
| JP2018544554A Expired - Fee Related JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545230A Expired - Fee Related JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20190048085A1 (https=) |
| EP (3) | EP3420000A1 (https=) |
| JP (3) | JP7082574B2 (https=) |
| KR (2) | KR20180111870A (https=) |
| CN (3) | CN116082505A (https=) |
| AU (2) | AU2017223846A1 (https=) |
| BR (2) | BR112018067698A2 (https=) |
| CA (2) | CA3014067A1 (https=) |
| ES (1) | ES2903408T3 (https=) |
| RU (2) | RU2018128464A (https=) |
| SG (2) | SG11201807188VA (https=) |
| WO (2) | WO2017147383A1 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| US20190048085A1 (en) | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| TWI910495B (zh) | 2016-05-13 | 2026-01-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| GB201617714D0 (en) * | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| KR20240007775A (ko) | 2016-12-08 | 2024-01-16 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP7275043B2 (ja) | 2016-12-16 | 2023-05-17 | ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド | 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
| MA47604A (fr) | 2017-02-21 | 2020-01-01 | Regeneron Pharma | Anticorps anti-pd-1 pour le traitement du cancer du poumon |
| WO2018191619A1 (en) | 2017-04-13 | 2018-10-18 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| KR20190139216A (ko) | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법 |
| US12415844B2 (en) | 2017-12-20 | 2025-09-16 | Poseida Therapeutics, Inc. | BCMA specific VCAR compositions and methods for use |
| WO2019141774A1 (en) * | 2018-01-19 | 2019-07-25 | Miltenyi Biotec Gmbh | Regulatory t cell expressing a chimeric antigen receptor |
| CA3089230A1 (en) | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
| CA3095076A1 (en) * | 2018-03-29 | 2019-10-03 | Adagene Inc. | Anti-pd-l1 antibodies and use thereof |
| WO2019234580A1 (en) * | 2018-06-04 | 2019-12-12 | Diatheva S.R.L. | Anti-cd99 diabody or igg antibody and uses thereof |
| CA3104288A1 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP7003295B2 (ja) * | 2018-06-29 | 2022-01-20 | ワイ－バイオロジクス・インコーポレイテッド | Ｌａｇ－３に特異的に結合する単クローン抗体及びその用途 |
| AU2019301070B2 (en) | 2018-07-09 | 2025-09-11 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| SG11202103234RA (en) * | 2018-10-01 | 2021-04-29 | Adicet Bio Inc | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| AU2019359890B2 (en) | 2018-10-17 | 2024-10-24 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CN113226335B (zh) * | 2018-12-06 | 2023-10-13 | 广东天科雅生物医药科技有限公司 | 靶向肿瘤抗原、TGF-β、和免疫检查点的组合型TCR-T细胞疗法 |
| EP3902838A4 (en) | 2018-12-26 | 2022-12-21 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| JP7641223B2 (ja) * | 2019-01-28 | 2025-03-06 | サイフォス、バイオサイエンシズ、インコーポレイテッド | Ｃａｒ細胞上の非天然ｎｋｇ２ｄ受容体に、結合した異種分子を選択的に送達する改変非天然ｎｋｇ２ｄリガンド |
| US12589132B2 (en) | 2019-02-22 | 2026-03-31 | Five Prime Therapeutics, Inc. | CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors |
| US20220145325A1 (en) * | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| AU2020248448B2 (en) * | 2019-03-26 | 2026-01-29 | The Regents Of The University Of California | Chimeric antigen receptor modified T-cells (CAR-T) for the treatment of hematological and solid tumor cancers |
| CN110402892A (zh) * | 2019-04-30 | 2019-11-05 | 梁廷波 | 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法 |
| CN112079924B (zh) * | 2019-06-12 | 2024-02-06 | 苏州工业园区唯可达生物科技有限公司 | Pd-l1靶向结合剂及其用途 |
| JP7678768B2 (ja) * | 2019-07-02 | 2025-05-16 | テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド | 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| AU2020380288B2 (en) * | 2019-11-04 | 2024-02-01 | Inovio Pharmaceuticals, Inc. | Combination therapy to treat brain cancer |
| RU2733430C1 (ru) * | 2019-11-19 | 2020-10-01 | Общество с ограниченной ответственностью «Реал Таргет» | Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| EP4069294A4 (en) * | 2019-12-02 | 2024-07-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-l1 and methods of use thereof |
| WO2021130535A2 (en) * | 2019-12-28 | 2021-07-01 | Shanghai Cell Therapy Group Company Co., Ltd. | Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| CN120060368A (zh) * | 2020-03-23 | 2025-05-30 | 株式会社库利金 | 包含双特异性核酸分子的溶瘤病毒的结构 |
| AU2021252514B2 (en) * | 2020-04-06 | 2025-06-26 | Lung Biotechnology Pbc | Modular synthetic receptors and methods of use |
| AU2021256473A1 (en) * | 2020-04-17 | 2022-12-22 | The Council Of The Queensland Institute Of Medical Research | Immune cells with enhanced function |
| WO2021231975A1 (en) * | 2020-05-14 | 2021-11-18 | Virtuoso Binco, Inc. | Humanized cd38 and icam1 antibodies and uses thereof |
| EP4164696A1 (en) * | 2020-06-11 | 2023-04-19 | Innovative Cellular Therapeutics Holdings, Ltd. | Cell/gene therapies targeting mage-a4 peptide |
| WO2021262499A1 (en) * | 2020-06-25 | 2021-12-30 | Promab Biotechnologies, Inc. | Pd-l1-specific antibody and anti-pd-l1-car-t cells |
| WO2022011256A1 (en) | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| KR20230117107A (ko) * | 2020-11-04 | 2023-08-07 | 센티 바이오사이언시스, 인코포레이티드 | 단백질 페이로드 방출 |
| CN112375743A (zh) * | 2020-11-20 | 2021-02-19 | 山东省医学科学院附属医院 | 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用 |
| IL303149A (en) * | 2020-11-30 | 2023-07-01 | Fred Hutchinson Cancer Center | Pd-l1 binding peptides and peptide complexes and methods of use thereof |
| EP4323389A1 (en) * | 2021-04-15 | 2024-02-21 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | T-cell receptors specific for both rac1- and rac2-derived mutated epitopes |
| CN113234152B (zh) * | 2021-06-03 | 2023-05-02 | 天津科技大学 | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 |
| WO2023274387A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
| US20250179196A1 (en) * | 2021-07-30 | 2025-06-05 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
| IL310808A (en) | 2021-08-13 | 2024-04-01 | Inovio Pharmaceuticals Inc | Combination therapy to treat brain cancer |
| WO2023072043A1 (zh) * | 2021-10-26 | 2023-05-04 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| US20250127897A1 (en) * | 2022-01-28 | 2025-04-24 | The University Of North Carolina At Chapel Hill | Natural killer t-cells and methods of using the same |
| CN118005806B (zh) * | 2024-02-08 | 2026-01-30 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN120518751B (zh) * | 2025-07-23 | 2025-09-19 | 中国人民解放军军事科学院军事医学研究院 | 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| JP2006508638A (ja) | 2002-05-22 | 2006-03-16 | エスバテック・アーゲー | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| PT1907424E (pt) * | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| KR101523391B1 (ko) | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
| BRPI0813645A2 (pt) | 2007-06-25 | 2014-12-30 | Esbatech Alcon Biomed Res Unit | Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas |
| PL2307458T3 (pl) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| CA2728829C (en) | 2008-06-25 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
| EP3255060A1 (en) * | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) * | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| EP3326467B1 (en) | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR20220084444A (ko) * | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| EP3467124A1 (en) * | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| CN113684185A (zh) * | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| IL243311B (en) | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP4166148B1 (en) * | 2014-06-06 | 2026-02-18 | Memorial Sloan-Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| RU2715038C2 (ru) * | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| EP3189073B2 (en) | 2014-09-04 | 2025-06-11 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| JP2017529851A (ja) | 2014-09-26 | 2017-10-12 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
| EP3212774A4 (en) | 2014-10-31 | 2018-04-11 | Baylor College of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| EP3233900A2 (en) | 2014-12-19 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptors and methods of use thereof |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| US20190048085A1 (en) * | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
-
2017
- 2017-02-24 US US16/079,202 patent/US20190048085A1/en not_active Abandoned
- 2017-02-24 CN CN202211150762.0A patent/CN116082505A/zh active Pending
- 2017-02-24 US US16/079,210 patent/US11434294B2/en active Active
- 2017-02-24 ES ES17711573T patent/ES2903408T3/es active Active
- 2017-02-24 WO PCT/US2017/019301 patent/WO2017147383A1/en not_active Ceased
- 2017-02-24 CN CN201780012727.3A patent/CN108699153B/zh not_active Expired - Fee Related
- 2017-02-24 EP EP17710091.4A patent/EP3420000A1/en not_active Withdrawn
- 2017-02-24 EP EP17711573.0A patent/EP3420001B1/en active Active
- 2017-02-24 BR BR112018067698A patent/BR112018067698A2/pt not_active Application Discontinuation
- 2017-02-24 AU AU2017223846A patent/AU2017223846A1/en not_active Abandoned
- 2017-02-24 JP JP2018545230A patent/JP7082574B2/ja not_active Expired - Fee Related
- 2017-02-24 SG SG11201807188VA patent/SG11201807188VA/en unknown
- 2017-02-24 RU RU2018128464A patent/RU2018128464A/ru not_active Application Discontinuation
- 2017-02-24 KR KR1020187024673A patent/KR20180111870A/ko not_active Ceased
- 2017-02-24 EP EP21209739.8A patent/EP4086285A1/en not_active Withdrawn
- 2017-02-24 CA CA3014067A patent/CA3014067A1/en active Pending
- 2017-02-24 SG SG11201807187XA patent/SG11201807187XA/en unknown
- 2017-02-24 AU AU2017224843A patent/AU2017224843A1/en not_active Abandoned
- 2017-02-24 JP JP2018544554A patent/JP7080819B2/ja not_active Expired - Fee Related
- 2017-02-24 WO PCT/EP2017/054367 patent/WO2017144681A1/en not_active Ceased
- 2017-02-24 CN CN201780012682.XA patent/CN108884164B/zh not_active Expired - Fee Related
- 2017-02-24 CA CA3014001A patent/CA3014001A1/en active Pending
- 2017-02-24 RU RU2018128462A patent/RU2018128462A/ru not_active Application Discontinuation
- 2017-02-24 KR KR1020187027644A patent/KR20190003938A/ko not_active Ceased
- 2017-02-24 BR BR112018067696A patent/BR112018067696A2/pt not_active Application Discontinuation
-
2022
- 2022-05-30 JP JP2022088103A patent/JP2022116230A/ja active Pending
- 2022-08-30 US US17/823,355 patent/US20230235061A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515646A5 (https=) | ||
| JP6681433B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| JP2022512653A5 (https=) | ||
| JP2022122927A (ja) | Ｃｄ３結合抗体 | |
| JP2017536341A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| JP2021510710A5 (https=) | ||
| JP2018183173A5 (https=) | ||
| JP2017522892A5 (https=) | ||
| JP2009225799A5 (https=) | ||
| JP2019510733A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JP2017526339A5 (https=) | ||
| JP2019513009A5 (https=) | ||
| JP2021514973A5 (https=) | ||
| JP2010500876A5 (https=) | ||
| JP2018537421A5 (https=) | ||
| JP2018537421A (ja) | Ｇｉｔｒアゴニスト | |
| JP2017519501A5 (https=) | ||
| JP2017529838A5 (https=) | ||
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| JP2013527761A5 (https=) | ||
| JP2017518040A5 (https=) | ||
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| RU2021129189A (ru) | Антитела против фактора свертывания xi |